# Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

> **NCT03005873** · PHASE2 · COMPLETED · sponsor: **Taiwan Liposome Company** · enrollment: 76 (actual)

## Conditions studied

- Osteoarthritis of the Knee

## Interventions

- **DRUG:** TLC599 LD group
- **DRUG:** Normal Saline
- **DRUG:** TLC599 HD group

## Key facts

- **NCT ID:** NCT03005873
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-16
- **Primary completion:** 2018-07-04
- **Final completion:** 2018-07-04
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03005873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03005873, "Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03005873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*